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Abstract
The development of resistant strains of HIV is the most significant barrier to effective long-term treatment of HIV infection.
The most common causes of resistance development are patient noncompliance and pre-existence of resistant strains. In
this paper, methods of antiviral regimen switching are developed that minimize the risk of pre-existing resistant virus
emerging during therapy switches necessitated by virological failure. Two distinct cases are considered; a single previous
virological failure and multiple virological failures. These methods use optimal control approaches on experimentally
verified mathematical models of HIV strain competition and statistical models of resistance risk. It is shown that,
theoretically, order-of-magnitude reduction in risk can be achieved, and multiple previous virological failures enable greater
success of these methods in reducing the risk of subsequent treatment failures.
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Introduction
The development of multi-drug regimens for HIV therapy has
resulted in HIV infection becoming a chronic, manageable disease
in first world countries [1]. The necessity of a three-drug regimen,
where each drug in the regimen targets separate viral epitopes, is
due to the extremely high replication and mutation rates
characteristic of HIV infection [2]. These make the evolution of
viral strains resistant to a single drug inevitable. Three drugs,
however, present a mutational barrier high enough to make such
an evolutionary occurrence unlikely [3,4]. These combinations
contain three drugs from at least two separate classes of antivirals,
including the nucleoside/nucleotide analog reverse-transcriptase
inhibitors (nRTI), non-nucleoside reverse-transcriptase inhibitors
(NNRTI), protease inhibitors (PI), and integrate inhibitors (II).
While these three- drug regimens, known as highly active
antiretroviral therapy, or HAART, are highly effective at
suppressing the virus in the long term, some patients nevertheless
experience viral load rebound, driven by the emergence of a viral
mutant resistant to all three components of their HAART
regimen.
Mutation
Mutation events in HIV replication appear to be dominated by
point-substitution events, which occur with very high frequency.
This, coupled with the high turnover rate of HIV in uncontrolled
infection, create a situation in which multi-drug resistant virus
develops frequently. When a resistant mutant emerges, it becomes
necessary to switch to a new three-drug regimen, whose
components exhibit no cross-resistance with the failed three-drug
regimen [5]. There are a limited number of independent drug
combinations. A patient who has developed viral strains resistant
to all such combinations is called Multi-Drug Resistant or MDR,
and such patients are left with few viable treatment options. It is
critical, therefore, to preserve the remaining pool of independent
HAART regimens, especially for patients who have experienced
virological failure on more than one previous regimen.
Attempts have been made to re-sensitize the virus to
previously failed regimens through the use of treatment
interruptions; the theory is that the wild-type virus, which
enjoys a competitive advantage in the absence of therapy, would
re-establish dominance and potentially drive the resistant virus
extinct through competition [6]. Although these studies showed
a brief return of susceptibility, the resistant strain quickly
returned upon re-introduction of the drug regimen, and overall
patient outcome was worse than a non-interrupted control
group. More recent approaches have focused on changing the
genetic makeup of the viral pool in MDR patients in
preparation for 4-9 drug rescue regimens known as Mega-
HAART or giga-HAART [7,8], [9], [10], [11], [12]. These
approaches showed mixed results, mostly with poor clinical
outcomes. All of these previous approaches attempted to use
treatment interruptions to manipulate the susceptibility of the
virus to regimens consisting of drugs to which resistant virus had
already emerged. None of these addressed the possibility of
using interruptions to preserve the usefulness of a naive antiviral
regimen. Also, the antiviral regimen introduced following the
interruption was always novel, implying an attempt to
manipulate susceptibility by genetic profile alone, as opposed
to manipulating viral load and genetic profile.
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novel combinations in order to preserve some usefulness from
previously failed treatments in MDR patients. The problem with
this, however, is that the existing mutations represent a lowering of
the mutational barrier. The only way to overcome this in the long-
term seems to be an increase in the number of drug components
used, which may succeed at the goal of reducing viral load at the
cost of raising the side effects of the HAART drugs to an
unacceptable level. A notable exception to this was the recent
Tetriz study [13]. In this study, a drug combination using
components from previously failed regimens, including two drugs
for which the resistance mutations were known to be antagonistic.
Despite the use of only four previously failed components, this
regimen succeeding in inducing complete viral suppression in a
significant portion of the study group, strongly suggesting the
usefulness of permuted regimens. The importance of preserving
suppressive regimens has driven a number of clinical studies,
including the SWATCH study [14], which showed reduced
incidence of virological failure in patients undergoing a pre-
emptive switching schedule based on mathematical models of risk
similar to those described in the Analysis section.
Competition and Selection
The development of drug resistance in HIV infection is driven
by two phenomenon: mutation and selection. Mutation in HIV
replication occurs at a well-characterized, relatively constant rate
of approximately 3   10{5 substitutions per base-pair per
replication cycle [15]. Other mutation types, such as deletions,
insertions, and rotations, happen with considerably lower
frequency, and do not usually contribute to the development of
resistance. Despite this relatively high rate of mutation, the
population of virus in a treatment-naive patient contains only virus
with very few genetic changes from the nominal, or ‘‘wild-type’’
HIV sequence. This is due to the influence of selection; the wild-
type dominates in the absence of treatment because it is usually the
fittest virus in that environment. Many mutations carry a fitness
cost when compared to the wild-type sequence; viruses carrying
these mutations do not replicate as efficiently as the wild-type
virus. The various virus subtypes compete for target cells, so
selective pressures tend to drive extinct virus variants that carry
mutations.
When antiviral medication is used, the wild-type is no longer the
fittest virus; their interference with the virus’ ability to replicate is
such that the virus population will shrink exponentially. Various
mutations exist that, if present, reduce the ability of the antiviral
drugs to interfere with HIV replication; if they interfere to the
extent that the mutant virus population is able to grow overall, the
mutation can provide clinically significant resistance.
Genetic Distance and Fitness Cost
The likelihood of a particular resistance mutation emerging is
influenced by two major factors. The first is the relative fitness of
the mutation under the current treatment. This may be calculated
by considering the relative effectiveness of the mutation at
negating the effect of the drug and the relative fitness cost of the
mutation. Fitness cost, in this sense, means the decrease in the
viruses’ ability to effectively replicate in the absence of treatment as
a result of the mutation.
The second factor influencing likelihood of emergence is the
genetic distance of the resistance mutation from the existing virus
pool. This is the number of point mutations necessary to generate
the resistance mutation. If the HIV genome is considered to reside
in a sequence space, the genetic distance is equivalent to the
Hamming distance. Because mutation is a random process,
mutations with a high genetic distance are very unlikely to emerge.
Example Strains from the Stanford database. Extensive
data on resistance mutations to the antivirals listed above has been
collected online at the Stanford HIV database [16]. An example
from the database can illustrate the genetic distance calculations
referenced above. Consider a patient who developed viral
resistance to an initial therapy consisting of the NRTIs abacavir
and lamivudine and the NNRTI nevirapine (this is a standard first-
line therapy). According to the database, one set of mutations
yielding significant resistance to these three drugs is
(74V,103N,184V), that is, a substitution of valine for leucine in
position 74 of the viral reverse transcriptase protein, a substitution
of asparagine for lysine in position 103, and a substitution of valine
for methionine in position 184. Together, these mutations require
at least three point substitutions from the wild-type genome (the
number may be higher, as multiple sequences may code for the
same amino acid), giving us a genetic distance of 3.
Since the (103N) mutation gives broad class resistance against
all NNRTIs, any follow-up therapy will not use NNRTIs. Neither
(74V) nor (184V) exhibit strong cross-resistance patterns with any
other NRTIs, so a possible follow-up therapy would be the two
NRTIs tenofovir and zidovudine together with the PI nelfinavir.
Clinically significant resistance to these three drugs could be
conferred by the set of mutations (41L,210W,215Y) on the viral
RT protein and the mutation (30N) on the viral protease protein.
This set of mutations has a genetic distance of 4 from the wild-
type, but a genetic distance of 6 from the mutant virus generated
in the first round of treatment. This is because the inclusion of
either the (74V) or the (184V) mutation increases the susceptibility
of the virus to both tenofovir and zidovudine. Consequently, any
resistant virus arising to the second treatment will probably arise
from the wild-type viral pool, and will probably not carry the
(74V), (103N), or (184V) mutations.
Therefore, after developing resistance sequentially to these two
treatment regimens, the patient will be carrying three viral strains;
the wild-type, one mutant carrying the (74V,103N,184V) RT
mutations and another mutant carrying the (41L,210W,215Y) RT
mutations and the (30N) Protease mutation,. A resistance mutation
to a third antiviral schedule consisting of a permutation of the first
tworegimens,sayabacavir,zidovudine,and nevirapine,wouldhave
to arise from one of these parent viruses. The common resistance
mutation to this combination with the closest genetic distance to the
wild-type carries the mutations (70R, 103N, 184V, 215F) would
have a genetic distance of 5. This is also the variant with the shortest
genetic distance to the first mutant, with a genetic distance of 4 (the
inclusion of the 74V mutation eliminates the resistance to
zidovudine, so it must be undone to confer resistance). The variant
with the shortest genetic distance to the second mutant would carry
theRT mutations(41L,103N,184V,210W,215Y),and would have a
geneticdistanceofeither2or3,dependingonwhethertheprotease-
resistance mutation renders it inviable.
Genetic Distance Uncertainty. The computation of genetic
distance between HIV strains is relatively straightforward, but
there are a few ways in which the genetic distance can be over- or
under-estimated. The first is the non-uniqueness of the genetic
code; multiple genomic sequences can code for the same amino
acid. The calculations carried out in the previous section assumed
the parent genome contained the sequence with the shortest
genetic distance to the mutant; this may lead to an under-
estimation of genetic distance.
When using genetic distance to estimate mutational barriers, as
described in the next section, the existence of viable transitional
forms can result in an overestimation of genetic distance. That is,
Risk-Optimal Antiviral Switching in HIV
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high, an unidentified partially resistant strain with a lower genetic
distance may provide a ‘‘stepping-stone’’ for the development of
the fully resistant strain.
Analysis
Computation of Risk as a function of Viral Load
Pre-existence. The research of Bonhoeffer and Ribeiro [17],
[3] show that emergence of resistant virus strains is most likely
caused by preexistent resistant mutants under very general
conditions. Bonhoeffer [17] also stated that the preexistence does
not mean that there is a stable coexistence of sensitive and resistant
virus. The preexistence of resistant mutant is made from mutations
between sensitive and resistant mutant. Therefore, in order to
quantify the risk of drug-resistance emergence, resistance
mutations must be modeled as a stochastic process.
Poisson Modeling. In this section, equations are presented
that determine the drug-resistance emergence risk, which is the
mutation probability from the current virus pool to a resistant
mutant for the new regimen. To accomplish this, a Poisson
distribution is used to model the mutation process. The probability
of pre-existing resistant genotypes depends upon two key variables:
the total number of active virions for each type of virus present in an
infected host, v1,v2,:::vn, and the point genetic distance from the
current virus strains to the emergent resistant mutant ve: g1,g2,:::gn.
Based on the research of [18], [19],[20], [21], the total viral burden
can be estimated. The total viral burden of actively circulating virus
can be roughly calculated as the viral titer multiplied by the volume
distributionoftotalbodyextracellularfluidwhichis25-30%ofbody
mass [21]. For example, a 100-kg man (roughly 100-liter volume)
with a viral RNA load 10000 copies/ml would have (100000|
10000|0:3) circulating virions approximately.
Therefore, assuming a point mutation rate of m, the probability
of drug-resistance emergence risk is calculated as follows:
P(ve(St)=0jvi(St)) ~ 1{e{lr,
lr ~
P n
i~1
vi(St)mgi ð1Þ
where vi(St) is the viral load of virus subtype vi present in the
patient at the time of introduction of the naive regimen, St.
Consider the simplest case. Assuming that the current virus pool
consists of only one kind of virus strain and the genetic distance
from the current virus strain to the resistant mutant is either 1, 2 or
3. Fig. 1 shows the relationship between viral load and the risk of
resistant mutant emergence.
As Fig. 1 shows, the resistant mutant may pre-exist when the
point genetic distance is 1 or 2, but the pre-existence of resistant
mutants is very unlikely if the point genetic distance is 3 or bigger.
Consider the case where the current virus are all wild-type and the
point genetic distance is 2 between the wild-type virus and a
mutant resistant to the naive regimen. If the patient is switched to
the naive regimen when the viral load is 30000 copies/ml, the
probability that the resistant mutant will preexist is 64.11%.
However, if the switch is made when the viral load is 2000 copies/
mL, the risk is only 6.86%. Therefore, the task is to create a switch
point for the new regimen with the lowest risk.
Model
To model HIV dynamics, a set of ordinary differential
equations is used that includes terms describing the mutations
among different virus types. This model depicts the interactions
between a wild-type virus population sensitive to all antiviral drug
regimens and a resistant mutant virus population only sensitive to
treatment with some, if any, antiviral drug combinations. The
model is in shown in Equation 2
_ x x ~ l{dx{bw(1{jw,1u1)(1{jw,2u2)xvw
{br(1{jr,1u1)(1{jr,2u2)xvr
_ y yw ~ bw(1{jw,1u1)(1{jw,2u2)xvw{awywzlw
_ y yr ~ br(1{jr,1u1)(1{jr,2u2)xvr{aryrzlr
_ v vw ~ cwawyw{vwvw
_ v vr ~ craryr{vrvr
ð2Þ
This model includes states x, representing CD4+ T cells that are
susceptible to infection; yk, the CD4+ T cells infected by the virus
type vk, and vk, the kth type of virus in the patient’s virus pool.
k~w for wild-type virus and k~r for resistant mutant viruses.
The definition of each parameter, and its units, may be found in
Table 1.
CD4+ T cells are generated from their source at rate l and
disappear at rate d. The target cells are infected by the viral strain
vk at rate of bk and the therapy suppresses the infection by strain vj
with efficacy jk,iui, where jk,i is the maximum effectiveness of
antiviral regimen ui on virus strain vk.
The infected CD4+ T cells yk are created first by the infection
from target cells x with virus vk that are generated at a rate bk.
Secondly, there is a contribution due to the activation from long-
lived reservoirs at rate lk. The infected CD4+ T cells die with a
rate of ak.
The virus vk are created from infected CD4+ T cells yk. Virus,
vk, die with a rate of vk. These equations are arbitrarily scalable to
any number of viral species.
Model identification parameters. To apply the system of
equations describing the evolution of viral loads and CD4+T cells
to a specific individual, the parameters of the nonlinear differential
equations need to be estimated. Using patient data from the
AutoVac study [22], a Bayesian estimation technique (specifically,
the MCMC, Monte Carlo Markov Chain, method) is used to
Figure 1. Resistance emergence risk vs. viral load.
doi:10.1371/journal.pone.0027047.g001
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HIV patients had viral load measurements taken at a 1-day
interval during a series of short treatment interruptions. The data
available for estimation is limited to a relatively few values of viral
loads after an interruption of medication and reintroduction. In
this work, the approach of Huang [23] is used in applying a
Bayesian nonlinear mixed-effects model. For the simplified
model, there are six parameters to estimate: l, the generation
rate of the target cells, d, the death rate of the target cells, bw,t h e
infection rate for the wild type virus, aw, the death rate of the cells
infected with the wild type virus, cw, the number of viral particles
emitted per infected cell, and vw, the death rate of viral particles.
The generation rates for the wild and resistant virus from long-
term reservoirs are assumed to be a small, known constant, and j
is assumed to be 1. Since the data is so limited, the parameters for
the resistant virus are not identified from the data. Instead, they
are assumed for the purposes of this paper to be proportional to
the parameters for wild-type according to the ratio of viral fitness,
with a nominal ratio of 0.5. In practice, this ratio could be
estimated from in vitro fitness data available for most common
mutation patterns.
Parameter estimates were generated for each of 12 patients. For
each patient, treatment was interrupted and after a period of time,
the treatment was restarted. This cycle of interrupting and
reinstating the treatment is repeated 3 or 4 times. The MCMC
procedure produced 200,000 possible combinations of parameters
that are consistent with the patients’ data. From this result, the
marginal probability densities for of the six parameters can be
established. Among the 12 patients, 3 of them have no detectable
virus after an interruption and another 3 appear to be subject to
multiple large exogenous disturbances (likely viral blips) which are
not accounted for in our model, and result in poor fits. The results
of the other 6 patients by using this identification method are
shown in Fig. 2.
Multiple previously failed therapies
In the case of patients who have failed one or more drug
regimens previously, the need to preserve the remaining regimens
becomes all the more important. Interestingly, the previously
failed regimens provide additional control inputs which can be
used to reduce the risk of failure for the new regimen at a lower
systemic cost than is possible when only one failing regimen is
available to use.
Regimen Cycling. The multiple failed regimens allow two
options for achieving a transient reduction in viral load. Cycling
through the previously failed regimens before returning to the
currently failing regimen is one such option. Consider a patient
with viral dynamics described by Equation 2 who has developed
virus strains vr1 and vr2 resistant to two previous treatment
regimens u1 and u2. If the viral strains resistant to those regimens
are susceptible to the current regimen, they will have decayed to
very low levels, and will take some time to re-emerge. Assuming no
cross resistance, the currently dominant viral strain is likely
susceptible to the original drug regimen u1 to which the strain vr1
developed resistance. Strictly speaking, so long as R0(vr1,u1)w
R0(vr2,u1) and R0(vr1,u2)vR0(vr2,u2), where R0 is the basic
reproductive ratio defined as
R0(vi,uj)~
bilci(1{ji,juj)
daivi
ð3Þ
then a transient viral minimum significantly lower than the steady-
state level of viral load may be achieved by this method [24].
Our approach can be formulated as an optimal control problem
in two steps. In the first step, the allowable patterns of treatment
cycling where either u1(t)~1 or u2(t)~1 at any time t are searched
to find a treatment pattern that minimizes the cost function
min
StƒTM,u1( ),u2( )
P(ve(St)=0jvi(St)), ð4Þ
where P(ve(St)=0jvi(St)) is the cost function defined by Equation
1 and St is the time to introduce a naive regimen. In Fig. 2, St1
and St2 represent the time to introduce a naive regimen in current
treatment strategy and our proposed treatment strategy respec-
tively. If the genetic distances between the closest strain resistant to
regimen u3 and vw,vr1, and vr2, respectively are all equal, this
optimization returns the treatment cycling schedule with the
largest decrease in total viral load prior to introducing the naive
regimen, as seen in Fig. 3. If a naive regimen was not introduced at
St2, the viral load would rebound shown as red-dash line in Fig. 3.
The treatment schedule may be fixed, or may change as the
optimization horizon TM increases, based on the actual values of
the parameters in Equation 4 [25]. Since treatment switching on
intervals faster than 1 day is not practical, the controls space is
discretized at 1 day intervals. This yields an optimization problem
with a finite search space, which can be solved in real time using
exhaustive search techniques. The second step involves robustly
estimating the time at which the minimum in the risk is achieved,
and switching to the naive regimen at this point. This study is a
subject for future research.
The achievable minimum according to this method will be
limited by the initial load levels of the various resistant viruses vri.
These in turn are determined by the length of time they have been
under suppressive therapy, and their relative prevalence in the
viral reservoirs. Using a cycling approach to achieve a risk
minimum requires tolerating a relatively high viral load for a short
period of time, which may contribute to disease progression or
increased resistance.
Permuted Regimen Introduction. A better option for
inducing a transient minimum in the case of multiple previously
failed regimens is to introduce a permuted antiviral regimen. It is
very likely that that no strain exists which is resistant to
permutations of the previously failed therapies. While an
antiviral regimen consisting of the permuted components of
previous regimens will not provide sufficient mutational barrier to
be a viable long-term option, they will allow a dramatic transient
reduction in the total viral load, and the corresponding risk of pre-
existent resistance.
In the mathematical formulation, the same cost function as
Equation 4 is applied. However, the simplified model is not
applicable for this case, because u1 and u2 are efficacies of drug
cocktails. In this case, ui is the efficacy of an individual drug.
Therefore, Equation 2 is modified as follows:
_ x x ~ l{dx{
P
0ƒjƒn
bjxvj( P
0ƒiƒn
(1{jj,iui))
_ y yk ~ bk( P
0ƒiƒn
(1{jk,iui))xvk{akykzlk
_ v vk ~ ckyk{vkvk
ð5Þ
In this model, there are multiple virus strains, vi, where
i~1,2,3,:::, corresponding to wild-type and all existing resistant-
Risk-Optimal Antiviral Switching in HIV
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long-live reservoir, and ui is the efficacy of the ith individual drug.
The optimization is performed to achieve the minimum cost
function defined by Equation 4 by exhaustively searching the
possible schedules for each individual drug.
When utilizing permuted regimens, the optimal switching
strategy involves switching from the failing regimen directly to a
permutation of previously failed regimens prior to introduction of
the naive regimen. Every previously dominant strain will be
susceptible to this permuted regimen, so this will result initially in
exponential decline in the total viral load. However, the reduced
genetic distance inherent in using components of previously failed
regimens means that resistance to the permuted regimen is likely to
emerge.Theexpected achievableriskreductioncanbeestimatedby
assuming that the strain resistant to the permuted regimen pre-
exists, with initial conditions related to measures of genetic distance.
Assuming that the two previously dominant resistant strains vr1
and vr2 are resistant to drug combinations a+b+c and A+B+C,
respectively, then virus resistant to a permuted drug combination
such as A+b+c will pre-exist with expected initial viral load
Table 1. State and parameter definitions for Equation 2.
Symbol Definition Unit
x Susceptible CD4+ T cells cells   mL{1
yk CD4+ T cells infected by the kth-type virus cells   mL{1
lk Contribution from the long-lived reservoirs of the kth-type virus cells   mL{1   d{1
vk Viral load of the kth-type virus copies   mL{1
l CD4+ T-cell generation rate cells   mL{1   d{1
d CD4+ T-cell death rate d{1
bk The kth-type virus infection rate copies{1   mL   d{1
jk,i Efficacy of the ith drug regimen on the kth-type virus
ui The ith antiviral drug regimen dosing
ak The kth-type infected cell virus-induced death rate d{1
ck The proliferation rate of the kth-type virus copies   cells{1
mmk,i Mutation rate between the kth and ith-type virus, d{1
where the point genetic distance is mk,i.
vk The kth-type virus decay rate d{1
doi:10.1371/journal.pone.0027047.t001
Figure 2. Model fitting for identified patients. Red star: experimental data (detection limit: 50 copies/mL); solid line: estimate. Unless otherwise
stated, examples in this paper use parameter values adapted from Patient 1: l~1:18   102, d~0:100, bw~3:52   10{6, br~3:52   10{6, aw~0:299,
ar~0:599, lw~0:063, lr~0:070, cw~297, cr~297, vw~1:14, vr~1:14.
doi:10.1371/journal.pone.0027047.g002
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vA{vr1 jj Hvr1(t)zm
vbc{vr2 jj Hvr2(t), ð6Þ
where m is the pointwise mutation rate for HIV and vA{vr1 jj H is
the number of point mutations in virus variant vr1 necessary to
generate a virus vA with resistance to drug A and vbc{vr2 jj H is the
number of point mutations in virus variant vr2 necessary to
generate a virus vbc with resistance to drugs b and c, respectively.
Note that these are also the Hamming distances applied to the
genetic sequences of the respective viruses. Fig. 4 shows the case
where only one point mutation separates the dominant resistant
strain from a strain resistant to the permuted regimen. Standard
treatment introduces a naive regimen at switch point S1.B y
introducing a permuted regimen at S1, it is possible to achieve a
greater than 2 order-of-magnitude reduction in viral load before
introducing the naive regimen at S2. The permuted regimen
provides insufficient mutational barrier to prevent resistance, so if
a switch is not made, the viral load will rebound. The reduction in
resistance emergence risk achieved by this intervention depends on
the genetic distance of the dominant strain at the switch time to
the closest strain with resistance to the naive regimen. Table 2
illustrates the achievable reduction in risk. It is clear that while a
genetic distance of 1 rules out any successful intervention, a genetic
distance of 2 or three allow a greater than 2 order-of-magnitude
reduction in the risk. Especially in the case of a genetic distance of
2, this is a dramatic change in expected outcome.
Although current guidelines [26] suggest changing drugs when
the virus load exceeds some threshold values (e.g., 1000-5000
copies/mL), finding the exact time when the viral load reaches the
threshold is unlikely, because a patient during therapy is only
tested for viral load every 3 or 4 months. The equilibrium value of
the viral load can therefore be used as the comparison benchmark.
It is worth noting that the genetic distance of 1 between the
previous viral strains and a strain resistant to the permuted
regimen, as used in this example, represents a worst-case scenario
(if the genetic distance is 0, this method cannot be used). The
example from the Stanford database in the introduction illustrates
a real-world case where this distance could be 2 or higher, yielding
even greater reductions in viral load and the corresponding risk of
pre-existent resistance.
Frequent sampling for minimum finding. Both of these
methods use optimization to find schedules that create a transient
minimum in the total viral load. Successful implementation of
these methods require accurately finding the time when this
minimum occurs and switching to a naive regimen at that point.
The exact time point of the achieved minimum may vary
considerably from its calculated point due to parameter
variation and the stochastic uncertainty in calculating initial
values of emerging resistant virus [27,28]. Also, a feedback-free
application of the schedule would be disastrous if unanticipated
resistance to the permuted regimen is present, as this would result
in the patient having uncontrolled virus replication for the
duration of the schedule. The simplest method to avoid this is
sample the viral load frequently following introduction of the
permuted regimen, and switch to the naive regimen either when
viral load reduction ceases or when a desired reduction in viral
load is achieved.
One Previously failed therapy
The case where a patient has a single previously failed regimen
had been the focus of our previous studies [29]. The only strategy
that yields effective reduction of future mutation risk in this case
involves total treatment interruptions.
Treatment interruptions and optimal scheduling. Our
objective is to find a drug-switching schedule that yields the
minimum risk, which is calculated as shown in the method in the
Analysis section. For patients with only a single previously failed
regimen, this can be achieved only through the use of interrupted
schedules of treatment. The concept is identical to that driving the
regimen cycling approach described in the previous section, except
that periods of no treatment are allowed. If the resistant virus
generated during the previous therapy has associated fitness cost
Figure 3. Multiple Previous Failures with Cycling.
doi:10.1371/journal.pone.0027047.g003
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treatment allow the wild-type virus to re-establish dominance. Re-
introduction of the failing regimen will then result in a transient
decrease in total viral load before the resistant strain re-establishes
dominance.
As in the previous section, this is an optimal control problem in
two steps. The optimal schedules consist of an interruption of
length T1, to sensitize the virus, followed by the re-introduction of
the failing regimen, resulting in transient suppression of the
sensitized viral load. Before viral load rebound occurs, the naive
antiviral regimen is introduced at time T2, resulting in a greatly
reduced risk of subsequent virological failure. T1 is again
calculated to minimize the cost function of Equation 4, and T2
is the switching time that achieves this minimum.
An example is used to illustrate how our algorithm works. The
simplified model of Equation 2 is employed with the parameters
which are identified for Patient 1. Assume that the point genetic
distances vw{ve jj H~ vr{ve jj H~2. The optimal time for intro-
duction of the naive regimen is fixed by the initial conditions at
time T1. The optimal interruption length T1 changes as a function
of parameters; there may be a true optimum, or the optimal time
may be infinite, as shown in Fig. 5 [25]. Where there is no
minimum, the knee in the curve, where increased interruption
time yields only marginal benefit, dictates the switching time. Fig. 6
shows the associated optimal switching schedule, with viral load as
a function of time. In this case, the risk of resistance emergence is
reduced from almost 55.4% to 0.18% by applying our algorithm.
Evolutionary Risks. Treatment interruption regimens have
been associated with a high rate of resistance emergence [30], and
are consequently avoided in standard HIV therapy [26]. Careful
analysis of their use in this context is needed to avoid the possibility
of encouraging development of multi-drug resistant viral strains.
Discussion
We have presented methods to reduce the risk of drug resistance
emergence in HIV by manipulating the viral load prior to
introduction of a naive antiviral regimen. These methods rely on
creating a transient reduction in total viral load prior to
introduction of a naive regimen. If the patient has failed multiple
previous regimens, this may be accomplished either through
regimen cycling or the use of a permuted antiviral regimen. If the
patient has failed only a single previous regimen, this may be
accomplished through the use of interrupted therapy. The optimal
switching regimens are computed using simple model-based open-
loop optimal control algorithms. In all cases, the models predict
achievable order-of-magnitude reduction in the risk of resistance
to the naive regimen pre-existing its introduction.
The method proposed in this paper uses predictive models of
HIV evolution under conditions of dynamic treatment to find
treatment schedules that minimize the probability of certain
resistant strains emerging. The application of dynamical systems
and control to evolutionary systems will likely find broader
application, as problems of drug resistance continue to increase in
other areas of medicine.
While risk reduction should be achievable through any of these
three methods, regimen cycling and interrupted therapy carry an
increased risk of disease progression and/or further development
of resistant virus. For these reasons, initial clinical investigations
will focus primarily on the method of permuted regimens.
Nevertheless, the other two methods may be useful in certain
circumstances.
The problem of multi-drug resistance in HIV is extremely
widespread, and methods that preserve remaining suppressive
antiviral regimens have the potential to significant decrease
morbidity and mortality in the HIV-positive population. The
necessary next steps for implementing this method are outlined
below:
Implementation Issues and Future Works
The methods introduced in this paper have the potential to
significantly reduce the incidence of pre-existence related
treatment failure. The methods involving permuted regimens
could be applied to select groups of patients without significant
further work. These patients would have to be in a closely
monitored clinical situation, have a history of consistent viral
genotyping showing strain patterns amenable to this method, and
would have to be available for frequent viral load sampling. For
these methods to be more broadly applied, several issues involving
measurement, viral load history, and sampling frequency will need
to be addressed.
Unmodeled Phenomenon. The model of Equation 2
represents a highly reduced form of the HIV dynamics, and
neglects many known factors in HIV infection. Perhaps chief
among these is the immune response to HIV, which can change
the infection rate b and the death rate of infected cells a
significantly. There is some previous work suggesting that the
immune response can change dynamically with respect to changes
in viral load, and that the consequences of this can be significant,
potentially leading to immunological control of the virus under
some circumstances [31–33]. However, multiple previous
experiments summarized in [34] show that, once the chronic
infection stage is reached, the immune system is permanently
damaged and no longer displays such dramatic dynamic response
Figure 4. Multiple Previous Failures with Permuted Regimens.
Blue line = Standard Treatment. Red Line = Permuted Regimen
Treatment. Green Line = Viral Load Rebound.
doi:10.1371/journal.pone.0027047.g004
Table 2. Probability of resistant strain pre-existence at each
switch point vs. genetic distance.
Genetic Distance 1 2 3
Switch Point S1 1 0.93 8:83   10{5
Switch Point S2 1 0.0089 3:04   10{7
doi:10.1371/journal.pone.0027047.t002
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over several successive treatment interruptions shown in Fig. 2
argues strongly for the sufficiency of the model of Equation 2 to
predict the dynamics of HIV during therapy changes.
Furthermore, the algorithm proposed in this paper does not
actually depend on the exact form of the model, but uses a closed-
loop sampling method to find the viral load minimum, and is
therefore robust to unmodeled phenomenon such as a changing
immune response.
Measurement issues. The methods described in this paper
rely heavily on the frequent and accurate measurement of the HIV
viral load, both for risk computation and model identification.
Viral load measurements are complicated by the existence of a
detection limit of 50 copies/mL. Targeting viral load reduction
below the limit of detection is therefore problematic. However,
reduction of viral load to this limit of detection is sufficient in most
cases to achieve a significant order-of-magnitude reduction in risk.
A second issue related to measurement is the proportion of the
measured viral load which is noninfectious. Cells with defective
integrated viral genomes may produce replication-incompetent
virus particles, and a proportion of the particles produced by all
infected cells will also be replication-incompetent. The most direct
measurement of this phenomenon estimates that between 5–13%
of the total free virus particles are capable of successfully
completing the infection process (a much lower percentage
actually complete the process, due to high inefficiencies at each
intermediate step of replication) [35]. If a model of HIV dynamics
is identified against plasma HIV RNA quantifications, which do
not differentiate between infectious and noninfectious particles,
then the estimate of the infection rate parameter b will implicitly
be multiplied by the percentage of plasma virions which are
infectious. This will not be a problem so long as all measurements
are consistent between the model identification and prediction;
estimated values of the number of infected cells will not be
affected. The method of action of protease inhibitors results in an
increase in the percentage of viruses which are noninfectious; this
reduced fraction will be implicitly captured in the estimated value
of the drug efficacy parameter j associated with the PI-containing
regimen. The proportion of measured virus that is non-infectious
will not affect the risk reduction algorithm, as the algorithm
attempts to minimize the measured virus prior to switching, which
is always proportional to the infectious virus. This phenomenon
will slightly alter the calculated risk associated with a given
measured viral load, but as the risk only depends logarithmically
on the viral load, the change due to this relatively small
proportional difference will be negligible.
A third issue, related to the second, is the fact that plasma viral
concentrations are not the same as the virus concentrations in the
lymphoid tissues, where the majority of the HIV virus resides and
the where the majority of virus dynamics occur. HIV virus
penetrates into many different tissues in the body, and there is
evidence that these tissues are sufficiently compartmentalized to
allow for divergent evolution of the virus in different compart-
ments [18–20].The conversion factor developed in [21] and used
in Equation 1 is a good first order approximation of the
relationship between plasma virus level and total viral burden. A
recent study in SHIV infected Rhesus Macaques has shown
excellent proportional correlation between viral concentrations in
plasma and various other tissue types both under treated and
untreated conditions [36], indicating that the plasma virus load is a
good surrogate measurement of total viral burden, even under
conditions of dynamic therapy. The exact ratio between plasma
viral load and total viral burden will change from patient to
patient, but this will not affect the proposed algorithm, though it
will slightly alter the calculated risk associated with a measured
viral load, as discussed above.
Choosing drug permutations. The most promising method
presented in this paper is the introduction of permuted antiviral
regimens prior to the introduction of a naive regimen. In order to
safely choose these permuted regimens, it is necessary to know
which resistant viruses are present in the patient’s viral reservoirs.
Consistent viral genotyping following every treatment failure
would provide this information; unfortunately, this is rare. It may
be possible to estimate the likely distribution of resistant viruses in
a patient based on a history of antiviral use and failure, using
genetic distance and fitness information from the HIV database.
Finding Minima. All the methods presented in this paper
induce a transient crash in the viral load, and depend on being
able to switch therapies at or near the minimum of this crash, prior
to rebound. In this paper, the method suggested for this is
consistent, frequent sampling of the viral load during the transient
period. While this should work, it is expensive both in economic
Figure 5. Achievable risk reduction as a function of interrup-
tion length.
doi:10.1371/journal.pone.0027047.g005
Figure 6. Optimal switching schedule. Treatment is interrupted at
time 0,and reintroduced at time T1. At time T2, naive treatment is
introduced, yielding an 2 order-of-magnitude reduction in risk.
doi:10.1371/journal.pone.0027047.g006
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methods to find the viral load minima with the fewest possible
measurements should solve this issue; this research is ongoing [37–
39].
Author Contributions
Conceived and designed the experiments: RZ RL. Performed the
experiments: RL MJP RZ. Analyzed the data: RL MJP JMP RZ.
Contributed reagents/materials/analysis tools: JMP. Wrote the paper: RL
MJP JMP RZ.
References
1. Gray C, Lawrence J, Ranheim E, Vierra M, Zupancic M, et al. (2000) Highly
active antiretroviral therapy results in HIV type 1 suppression in lymph nodes,
increased pools of naive T cells, decreased pools of activated T cells, and
diminished frequencies of peripheral activated HIV type 1-specific CD8+ T
cells. AIDS Res Hum Retroviruses 16: 1357–1369.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid
turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature
373: 123–126.
3. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during
antiretroviral therapy. Proc Natl Acad Sci USA 97: 7681–7686.
4. Ribeiro R, Mohri H, Ho D, Perelson A (2002) In vivo dynamics of T cell
activation, proliferation, and death in HIV-1 infection: why are CD4+ but not
CD8+ T cells depleted? Proc Natl Acad Sci U S A 99: 15572–15577.
5. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, et al.
(2006) Treatment for adult HIV infection: 2006 recommendations of the
International AIDS Society-USA panel. JAMA 296: 827–843.
6. Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and
immunologic consequences of discontinuing combination antiretroviral-drug
therapy in HIV-infected patients with detectable viremia. New Engl J Med 344:
472–480.
7. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, et al. (2003) Persistence
of drug-resistant HIV-1 after a structured treatment interruption and its impact
on treatment response. AIDS 17: 361–370.
8. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, et al. (2005) Interruption
of treatment with individual therapeutic drug classes in adults with multidrug-
resistant HIV-1 infection. J Infect Dis 192: 1537–1544.
9. Ghosn J, Wirden M, Ktorza N, Peytavin G, Aı ¨t-Mohand H, et al. (2005) No
benefit of a structured treatment interruption based on genotypic resistance in
heavily pretreated HIV-infected patients. AIDS 19: 1643–1647.
10. Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, et al. (2006) A
randomized trial of treatment interruption before optimized antiretroviral
therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG
A5086. J Infect Dis 194: 1309–1318.
11. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, et al. (2004)
Benefit of treatment interruption in HIV-infected patients with multiple
therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18:
217–226.
12. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, et al. (2003)
Structured treatment interruption in patients with multidrug-resistant human
immunodeficiency virus. N Engl J Med 349: 837–846.
13. Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, et al. (2008) Transient
treatment exclusively containing nucleoside analogue reverse transcriptase
inhibitors in highly antiretroviral-experienced patients preserves viral benefit
when a fully active therapy was initiated. HIV clinical trials 9: 387–398.
14. Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, et al. (2003)
Alternation of antiretroviral drug regimens for HIV infection. A randomized,
controlled trial. Ann Intern Med 139: 81–89.
15. Mansky LM (1996) Forward mutation rate of human immunodeficiency virus
type 1 in a T lymphoid cell line. AIDS Res Hum Retroviruses 12: 307–314.
16. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database.
J Infect Dis 194(Suppl 1): S51–8.
17. Bonhoeffer S, Nowak MA (1997) Pre-existence and emergence of drug resistance
in HIV-1 infection. Proc Biol Sci 264: 631–637.
18. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, et al.
(1994) Genetic differences between blood- and brain-derived viral sequences
from human immunodeficiency virus type 1-infected patients: evidence of
conserved elements in the V3 region of the envelope protein of brain-derived
sequences. J Virol 68: 7467–7481.
19. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, et al. (1996) Genetic
characterization of human immunode_ciency virus type 1 in blood and genital
secretions: evidence for viral compartmentalization and selection during sexual
transmission. J Virol 70: 3098–3107.
20. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, et al. (1997) In vivo
compartmentalization of human immunode_ciency virus: evidence from the
examination of pol sequences from autopsy tissues. J Virol 71: 2059–2071.
21. Colgrove R, Japour A (1999) A combinatorial ledge: reverse transcriptase
fidelity, total body viral burden, and the implications of multiple-drug HIV
therapy for the evolution of antiviral resistance. Antiviral Res 41: 45–56.
22. Ruiz L, Carcelain G, Martı ´nez-Picado J, Frost S, Marfil S, et al. (2001) HIV
dynamics and T-cell immunity after three structured treatment interruptions in
chronic HIV-1 infection. AIDS 15: F19–27.
23. Huang Y, Liu D, Wu H (2006) Hierarchical Bayesian methods for estimation of
parameters in a longitudinal HIV dynamic system. Biometrics 62: 413–423.
24. Zurakowski R, Wodarz D (2007) Treatment interruptions to decrease risk of
resistance emerging during therapy switching in HIV treatment. In: Proc. of the
46th IEEE Conference on Decision and Control. New Orleans, LA. pp
5174–5179.
25. Luo R, Zurakowski R (2008) A new strategy to decrease risk of resistance
emerging during therapy switching in HIV treatment. In: Proc. of the American
Control Conference. Seattle, WA. pp 2112–2117.
26. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the
International AIDS Society-USA panel. JAMA 300: 555–570.
27. Luo R, Piovoso M, Zurakowski R (2010) Modeling-error robustness of a viral-
load preconditioning strategy for HIV treatment switching. In: Proc. of the
American Control Conference. Baltimore, MD. pp 5155–5160.
28. Luo R, Cannon L, Hernandez J, Piovoso MJ, Zurakowski R (2011) Controlling
the evolution of resistance. Journal of Process Control 21: 367–378.
29. Luo R, Piovoso M, Zurakowski R (2009) A generalized multi-strain model of
HIV evolution with implications for drug-resistance management. In: Proc. of
the American Control Conference. St. Louis, MO. pp 2295–2300.
30. Ananworanich J, Nuesch R, Braz ML, Chetchotisakd P, Vibhagool A, et al.
(2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized
trial. AIDS 17: F33–7.
31. Wodarz D (2001) Helper-dependent vs. helper-independent CTL responses in
HIV infection: implications for drug therapy and resistance. J Theor Biol 213:
447–459.
32. Lifson J, Rossio J, Arnaout R, Li L, Parks T, et al. (2000) Containment of simian
immunodeficiency virus infection: cellular immune responses and protection
from rechallenge following transient postinoculation antiretroviral treatment.
J Virol 74: 2584–2593.
33. Lifson JD, Rossio JL, Piatak M, Parks T, Li L, et al. (2001) Role of CD8(+)
lymphocytes in control of simian immunodeficiency virus infection and
resistance to rechallenge after transient early antiretroviral treatment. J Virol
75: 10187–10199.
34. Zurakowski R (2011) Nonlinear observer output-feedback MPC treatment
scheduling for HIV. Biomed Eng Online 10: 40.
35. Thomas JA, Ott DE, Gorelick RJ (2007) Efficiency of human immunodeficiency
virus type 1 postentry infection processes: evidence against disproportionate
numbers of defective virions. J Virol 81: 4367–4370.
36. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral
sanctuaries during highly active antiretroviral therapy in a nonhuman primate
model for AIDS. J Virol 84: 2913–2922.
37. Rosero-Garcia E, Zurakowski R (2010) Closed-loop minimal sampling method
for determining viral-load minima during switching. In: Proc. of the American
Control Conference. Baltimore, MD. pp 460–461.
38. Cardozo EF, Zurakowski R (2011) Measurement error robustness of a closed-
loop minimal sampling method for HIV therapy switching. In: Proc. of the IEEE
Eng. Medicine and Biology Conference. Boston, MA. pp 116–119.
39. Zurakowski R, Churgin M, Perez C, Rodriguez M (2011) Approximate-model
closed-loop minimal sampling method for HIV viral-load minima detection. In:
Proc. of the American Control Conference. San Francisco, CA. pp 5418–5419.
Risk-Optimal Antiviral Switching in HIV
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27047